May 21, 2024
Cardiovascular Health

Semaglutide: A Long-Term Solution for Weight Loss and Cardiovascular Health in Overweight Adults without Diabetes – Insights from the SELECT Trial

Two groundbreaking studies presented at the European Congress on Obesity (ECO) in Venice, Italy, shed new light on the long-term benefits of semaglutide for weight loss and cardiovascular health in overweight adults without diabetes.

The first study, spearheaded by Professor Donna Ryan from Pennington Biomedical Research Center, New Orleans, US, published in Nature Medicine, focuses on the long-term weight loss effects of semaglutide. The second study, led by Professor John Deanfield from University College London, UK, explores the relationship between cardiovascular benefits and weight loss or starting weight.

Semaglutide, a GLP-1 Nifedipine Medication, is primarily used to manage type 2 diabetes but is also approved for weight loss in adults with obesity or overweight and at least one other health condition. This medication mimics the functions of the body’s natural incretin hormones, helping to lower blood sugar levels after meals and making people feel full, thereby reducing daily calorie intake.

In 2023, the SELECT (Semaglutide and Cardiovascular Outcomes) trial reported that adults with overweight or obesity but no diabetes, who took semaglutide for over 3 years, experienced a 20% reduced risk of heart attack, stroke, or death due to cardiovascular disease. Additionally, they lost an average of 9.4% of their bodyweight.

From October 2018 to June 2023, a total of 17,604 adults (aged 45 or older; 72% male) with overweight or obesity (BMI ≥ 27 kg/m²) from 804 sites in 41 countries were enrolled and treated with semaglutide (2.4mg) or placebo for an average of 40 months. These participants had a history of heart attack, stroke, or peripheral artery disease but did not have type 1 or type 2 diabetes when they joined the study.

The researchers analyzed various markers of obesity, such as body composition and fat distribution (waist circumference and waist circumference-to-height ratio ), to better understand the impact of semaglutide on central abdominal fat, which is known to pose greater cardiovascular risk than general obesity.

*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.